Solana leverages the helicase-dependent amplification technology that also underpins Quidel's AmpliVue molecular technology.
This is the first update to the guidelines since 2010, and the agency specifically calls out two of the three FDA-cleared Trichomonas NAATs.
The number of decliners in the GenomeWeb Index in April outpaced the gainers 24 to seven amid softness in the broader biotech market.
The presentations were part of a Quidel-sponsored workshop and poster sessions at the Clinical Virology Symposium in Daytona Beach, Fla.
New product revenues more than doubled year over year, while infectious disease test revenues grew 35 percent.
The trichomonas assay is Quidel's sixth assay running on the AmpliVue handheld molecular diagnostic device that has been cleared by the FDA.
Roche's investment in Foundation of up to $1.2B sent Foundation's stock soaring. Otherwise, firms in the GenomeWeb Index saw a mixed month.
The company expects revenues in the range of $63 million to $64 million for the fourth quarter and $182 million to $183 million for full-year 2014.
Trends included expanding test menus and a possible tipping point for point-of-care.
The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.
The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.
News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.
In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.